T3d
Benefits may vary, and results in the general population on CV risk and mortality are still
controversial.
Overall, the results of recent studies have been mixed results. Different study populations,
end points and dosing may account for the lack of clarity. #NephJC
My two little fish say hello… #NephJC
Hi. It’s been a long time… glad to be back to #nephJC
Hector Madariaga. Transplant kidney doc. Cambridge, MA
Comments in the NYT are also very interesting. One that caught my attention mentioned that current system is biased in favor of procuring organs in patients who are declared DCD. The cost of having no one prematurely referred for organ donation would be eliminating cadaveric donations altogether.
I don’t prescribe IT, but some of my patients are already on it. I have been calling it a non-essential medication, but maybe I should start prescribing fish oil!!! #NephJC
New Trump EO increases fee from $1,000 to $100,000 per year for H1B visas?? Aimed at tech companies hiring cheaper trained people.
However, this is going to be extremely disruptive to residency training programs and hospitals. Hope someone clues him in.
Throwing a fish to everyone… #NephJC
1/10
Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC
Read the article 👇
www.nejm.org/doi/10....
The NYT piece is a very sensational article & not well balanced. I believe it has caused more harm than good. I don’t blame people for criticizing the OPTN and OPOs—given all the issues you’ve mentioned, they deserve it—but the current system, albeit not perfect, works in 99% of cases. Should be 💯